TABLE 5.

Votes on Long-Term Value for Money at Current Prices

Question	Low	Intermediate	High
Given the available evidence on comparative effectiveness, incremental cost-effectiveness, and potential other benefits or disadvantages, what is the long-term value for money of treatment at current pricing with molnupiravir vs usual symptomatic care?	8	5	0
Given the available evidence on comparative effectiveness, incremental cost-effectiveness, and potential other benefits or disadvantages, what is the long-term value for money of treatment at current pricing with Paxlovid vs usual symptomatic care?	0	5	8
Given the available evidence on comparative effectiveness, incremental cost-effectiveness, and potential other benefits or disadvantages, what is the long-term value for money of treatment at current pricing with fluvoxamine vs usual symptomatic care?	1	7	5